← Back to Screener
CervoMed Inc. Common Stock (CRVO)
Price$3.98
Favorite Metrics
Price vs S&P 500 (26W)-59.91%
Price vs S&P 500 (4W)-10.49%
Market Capitalization$36.85M
All Metrics
Book Value / Share (Quarterly)$1.97
P/TBV (Annual)2.80x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)418.15%
Cash Flow / Share (Quarterly)$-2.53
Price vs S&P 500 (YTD)-53.76%
Gross Margin (TTM)-230.43%
Net Profit Margin (TTM)-1056.59%
EPS (TTM)$-2.97
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-2.97
Revenue Growth (5Y)61.03%
EPS (Annual)$-2.98
ROI (Annual)-147.98%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-1248.36%
Cash / Share (Quarterly)$2.25
Revenue Growth QoQ (YoY)-99.60%
ROA (Last FY)-117.87%
Revenue Growth TTM (YoY)-78.55%
EBITD / Share (TTM)$-3.13
ROE (5Y Avg)-73.02%
Operating Margin (TTM)-1100.61%
Cash Flow / Share (Annual)$-2.53
P/B Ratio2.02x
P/B Ratio (Quarterly)4.01x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)13.70x
Net Interest Coverage (TTM)-612.33x
ROA (TTM)-82.88%
EPS Incl Extra (Annual)$-2.98
Current Ratio (Annual)4.91x
Quick Ratio (Quarterly)4.64x
3-Month Avg Trading Volume0.07M
52-Week Price Return-58.06%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.69
P/S Ratio (Annual)9.20x
Asset Turnover (Annual)0.18x
52-Week High$13.13
Operating Margin (5Y Avg)-4529.28%
EPS Excl Extra (Annual)$-2.98
Tangible BV CAGR (5Y)28.99%
26-Week Price Return-51.17%
Quick Ratio (Annual)4.65x
13-Week Price Return-43.06%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.91x
Enterprise Value$28.614
Asset Turnover (TTM)0.07x
Book Value / Share Growth (5Y)-60.98%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.00x
Pretax Margin (Annual)-673.06%
Cash / Share (Annual)$2.25
3-Month Return Std Dev83.08%
Gross Margin (5Y Avg)-108.48%
Net Income / Employee (TTM)$-2
ROE (Last FY)-147.98%
Net Interest Coverage (Annual)18.75x
EPS Basic Excl Extra (Annual)$-2.98
Receivables Turnover (TTM)13.33x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.97
Receivables Turnover (Annual)8.00x
ROI (TTM)-96.04%
P/S Ratio (TTM)17.64x
Pretax Margin (5Y Avg)-1247.28%
Revenue / Share (Annual)$0.44
Tangible BV / Share (Annual)$14.87
Price vs S&P 500 (52W)-93.16%
Year-to-Date Return-49.62%
5-Day Price Return-0.75%
EPS Normalized (Annual)$-2.98
ROA (5Y Avg)-62.00%
Net Profit Margin (Annual)-673.06%
Month-to-Date Return1.02%
Cash Flow / Share (TTM)$-1.84
EBITD / Share (Annual)$-3.13
Operating Margin (Annual)-706.22%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-73.02%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.97
P/TBV (Quarterly)5.91x
P/B Ratio (Annual)4.01x
Inventory Turnover (TTM)0.00x
Pretax Margin (TTM)-1056.59%
Book Value / Share (Annual)$1.97
Price vs S&P 500 (13W)-45.93%
Beta-0.54x
Revenue / Share (TTM)$0.23
ROE (TTM)-96.04%
52-Week Low$3.51
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.07
4.07
4.07
4.07
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CRVOCervoMed Inc. Common Stock | 17.64x | -78.55% | -230.43% | — | $3.98 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
CervoMed is a clinical-stage biotechnology company developing treatments for age-related neurological disorders. Its lead candidate, Neflamapimod, is designed to address synaptic dysfunction in dementia with Lewy bodies and related neurological conditions.